SERB Acquires Y-mAbs: Rare Oncology Expansion
SERB Pharmaceuticals acquires Y-mAbs for $412M, gaining DANYELZA, an FDA-approved treatment for high-risk neuroblastoma, enhancing rare oncology portfolio.
Feed↓
/ What's going on?
Filter:
Pfizer's Profit Outlook Rises Amidst Strong Q2 Performance
Pfizer boosts its 2025 profit forecast due to ongoing cost reductions and strong second-quarter sales driven by top-performing drugs.
Caterpillar Q2 2025: Profit Miss, Tariffs Hit
Caterpillar's Q2 2025 adjusted earnings of $4.72/share missed estimates due to price declines & tariffs. Full-year tariff impact expected up to $1.5B. Demand remains resilient.
ThredUp Achieves Record Q2 2025 Results!
ThredUp announces stellar Q2 2025 financial results with record revenue, exceptional new buyer growth, and raised full-year outlook, driven by AI and thrifting trends.
Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat
Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.
Hims & Hers Q2: Profit Soars, Revenue Miss Sparks Share Drop
Hims & Hers' Q2 profit surged to $42.5M, fueled by 31% subscriber growth (2.4M total). Revenue of $544.8M missed estimates, impacted by wholesale weakness, causing shares to fall. Full-year guidance maintained.